06:20 AM EDT, 03/09/2026 (MT Newswires) -- GSK (GSK) said Monday that it has entered a license agreement under which Alfasigma will acquire the global exclusive rights to develop, manufacture and commercialize Linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis.

GSK said it will receive an upfront payment of $300 million, plus $100 million upon US FDA approval which is expected on March 24, before the closing of the transaction.

The company said it will also be eligible to receive $20 million upon EU and UK approval, up to $270 million in sales-based milestone payments, and earn tiered double-digit royalties on net sales worldwide.